Figure 5. JMJD2A binds to the FHL1 promoter in vivo.

(A) JMJD2A-chromatin complexes were immunoprecipitated from lysates of sham- and TAC-operated WT, control (Jmjd2a^fl/fl), Jmjd2a-Tg, and Jmjd2a hKO mouse hearts, with anti-JMJD2A antibody and quantified by qPCR with primers in the FHL1 promoter. The amounts of immunoprecipitated complex were normalized against DNA purified from sonicated cell lysates (input) and expressed as relative to that of sham-operated WT/control. (B) ChIP was performed on aliquots of lysates from A using an anti-H3K9me3 antibody. The amounts of chromatin in the FHL1 promoter associated with H3K9me3 were measured by qPCR, normalized against input, and expressed relative to that of sham-operated WT/controls. JMJD2A binds the FHL1 promoter in response to TAC, and binding of JMJD2A is associated with decreased levels of H3K9me3. Values are expressed as mean ± SEM of 3 independent experiments. *P < 0.05.